60 Degrees Pharmaceuticals and Fathom Holdings Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
ORLANDO, FL / / February 21, 2025 / RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, Inc. (Nasdaq:SXTP) and Fathom Holdings Inc. (Nasdaq:FTHM) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, February 22, at 7 p.m. Eastern Time (ET). Bloomberg TV is available in an estimated 73 million homes across the U.S.
Access the interviews in their entirety at:
SXTP: https://www.redchip.com/assets/access/sxtp_access
FTHM: https://www.redchip.com/assets/access/fthm_access
In an exclusive interview, Geoffrey Dow, CEO and President of 60 Degrees Pharmaceuticals, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss the company's mission to develop and commercialize new therapies for infectious diseases. He highlights the FDA-approved antimalarial drug ARAKODA® (tafenoquine) and outlines plans to expand its indications to address other diseases, including babesiosis. Dow also emphasizes the company's commitment to addressing unmet medical needs and improving global health outcomes.
Marco Fregenal, CEO of Fathom Holdings, appears on the RedChip Small Stocks Big Money™ show on Bloomberg TV to discuss the company's disruptive approach to real estate services. He highlights Fathom's innovative flat-fee commission model, which allows agents to retain more of their earnings while driving industry-leading growth and retention rates. Fregenal also details how Fathom's proprietary intelliAgent platform integrates residential brokerage, mortgage, title, and SaaS offerings to create a scalable, cost-efficient business model that outperforms traditional brokerages. Additionally, he outlines the company's aggressive expansion strategy, including the successful acquisition of My Home Group, projected to add $110 million in 2025 revenue, and a pipeline of over 100 potential acquisition targets. With interest rates stabilizing and home sales expected to rise, Fregenal discusses how Fathom is positioned to capture market share, drive operational efficiency, and enhance shareholder value through its unique technology-driven approach.
SXTP and FTHM are clients of RedChip Companies. Please read our full disclosure at https://www.redchip.com/legal/disclosures.
About 60 Degrees Pharmaceuticals, Inc.
60 Degrees Pharmaceuticals, Inc., founded in 2010, specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases that affect the lives of millions of people. 60 Degrees Pharmaceuticals, Inc. achieved FDA approval of its lead product, ARAKODA® (tafenoquine), for malaria prevention, in 2018. 60 Degrees Pharmaceuticals, Inc. also collaborates with prominent research organizations in the U.S., Australia, and Singapore. The 60 Degrees Pharmaceuticals, Inc. mission has been supported through in-kind funding from the U.S. Department of Defense and private institutional investors including Knight Therapeutics Inc., a Canadian-based pan-American specialty pharmaceutical company. 60 Degrees Pharmaceuticals, Inc. is headquartered in Washington D.C., with a majority-owned subsidiary in Australia. Learn more at www.60degreespharma.com. The statements contained herein may include prospects, statements of future expectations and other forward-looking statements that are based on management's current views and assumptions and involve known and unknown risks and uncertainties. Actual results, performance or events may differ materially from those expressed or implied in such forward-looking statements.
About Fathom Holdings Inc.Fathom Holdings Inc. is a national, technology-driven real estate services platform integrating residential brokerage, mortgage, title, and SaaS offerings to brokerages and agents by leveraging its proprietary cloud-based software, intelliAgent. The Company's brands include Fathom Realty, Encompass Lending, intelliAgent, LiveBy, Real Results, and Verus Title. For more information, visit www.FathomInc.com.
About RedChip Companies
RedChip Companies, an Inc. 5000 company, is an international investor relations, media, and research firm focused on microcap and small-cap companies. For 33 years, RedChip has delivered concrete, measurable results for its clients. Our newsletter, Small Stocks, Big Money™, is delivered online weekly to 60,000 investors. RedChip has developed the most comprehensive service platform in the industry for microcap and small-cap companies. These services include the following: a worldwide distribution network for its stock research; retail and institutional roadshows in major U.S. cities; outbound marketing to stock brokers, RIAs, institutions, and family offices; a digital media investor relations platform that has generated millions of unique investor views; investor webinars and group calls; a television show, Small Stocks, Big Money™, which airs weekly on Bloomberg US; TV commercials in local and national markets; corporate and product videos; website design; and traditional investor relation services, which include press release writing, development of investor presentations, quarterly conference call script writing, strategic consulting, capital raising, and more.
To learn more about RedChip's products and services, please visit:
https://www.redchip.com/corporate/investor_relations
"Discovering Tomorrow's Blue Chips Today"™
Follow RedChip on LinkedIn: https://www.linkedin.com/company/redchip/
Follow RedChip on Facebook: https://www.facebook.com/RedChipCompanies
Follow RedChip on Instagram: https://www.instagram.com/redchipcompanies/
Follow RedChip on Twitter: https://twitter.com/RedChip
Follow RedChip on YouTube: https://www.youtube.com/@redchip
Follow RedChip on Rumble: https://rumble.com/c/c-3068340
Subscribe to our Mailing List: https://www.redchip.com/newsletter/latest
Contact:
Dave GentryRedChip Companies Inc.1-407-644-4256info@redchip.com
--END--
SOURCE: RedChip
View the original press release on ACCESS Newswire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CNBC
9 minutes ago
- CNBC
Jim Cramer sees a 'bizarre' rotation in the market — plus, Starbucks makes a move in China
Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. ET. Here's a recap of Monday's key moments. 1. The stock market is starting the week relatively flat following Friday's rally due to a solid jobs report. Investors are awaiting trade news updates as American and Chinese officials gather in London . The flow of rare earth minerals out of China is a big focus of the talks. Within the stock market Monday, Jim Cramer said the action is interesting. "What I'm seeing is a kind of a very bizarre rotation. ... A lot of stocks that have been laggards like Texas Instruments are really taking off," Jim said. Meanwhile, stocks that had been certified winners are headed down. The rotation is "very daunting for people because you're buying lesser quality and selling high quality," Jim said. 2. Club name Starbucks has been on the recovering end lately, climbing nearly 7% last week and adding modest gains in Monday's session. In its latest move to navigate the competitive Chinese market, the company is cutting prices on non-coffee beverages in the country. The latest strategy is part of the coffee chain's campaign to win customers over during the summer. "It helps the story that they're doing some discounting," Jim said. It's no secret that Starbucks has had some difficulties in the region and has been looking for a strategic partner for its operations there. "I think [a partnership] would be well received by the market," said Jeff Marks, director of portfolio analysis for the Club. 3. It's a different story for portfolio name Broadcom , which closed 5% lower Friday after reporting earnings Thursday and is taking another hit Monday. Jim reminded members that on Friday he advised to hold off on buying into the stock's sell-off. "I said today's the day you buy," he said Monday. The company reported a strong quarter with AI revenue rising 46% year over year. Marks said the only real issue was the stock came into the print red hot, so it fell victim to high expectations, leading to the drop. However, the semiconductor manufacturer did see price targets raised at several firms Monday, including at Barclays, which went to $265 a share, up from $215. 4 . Stocks covered in Monday's rapid fire at the end of the video were: Warner Bros Discovery , Tesla , General Mills , and Conagra Brands . (Jim Cramer's Charitable Trust is long AVGO, SBUX . See here for a full list of the stocks.) As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. Jim waits 45 minutes after sending a trade alert before buying or selling a stock in his charitable trust's portfolio. If Jim has talked about a stock on CNBC TV, he waits 72 hours after issuing the trade alert before executing the trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB. NO SPECIFIC OUTCOME OR PROFIT IS GUARANTEED.
Business Wire
28 minutes ago
- Business Wire
Deadline Soon: Treace Medical Concepts, Inc. (TMCI) Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit
LOS ANGELES--(BUSINESS WIRE)-- The Law Offices of Frank R. Cruz reminds investors of the upcoming June 10, 2025 deadline to participate as a lead plaintiff in the securities fraud class action lawsuit filed on behalf of investors who acquired Treace Medical Concepts, Inc. ('Treace Medical' or the 'Company') (NASDAQ: TMCI) securities between , inclusive (the 'Class Period'). IF YOU ARE AN INVESTOR WHO LOST MONEY ON TREACE MEDICAL CONCEPTS, INC. (TMCI), CLICK HERE TO PARTICIPATE IN THE SECURITIES FRAUD LAWSUIT. What Happened? On May 7, 2024, after market hours, Treace Medical released its first quarter 2024 financial results and revised its full year 2024 guidance, lowering it by approximately $20 million, citing "increased use of MIS Osteotomy solutions and more competition from knockoffs of [the Company's] Lapiplasty products." On this news, Treace Medical's stock price fell $6.95, or 62.5%, to close at $4.17 per share on May 8, 2024, thereby injuring investors. What Is The Lawsuit About? The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) competition impacted the demand for and utilization of its primary product, the Lapiplasty 3D Bunion Correction System (the 'Lapiplasty'); (2) as a result, Treace Medical's revenue declined and the Company needed to accelerate its plans to offer a product that was an alternative to osteotomy (a surgical procedure that involves cutting and realigning a bone to improve its position or function); and (3) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times. If you purchased or otherwise acquired Treace securities between May 8, 2023 and May 7, 2024, the deadline to seek appointment as the lead plaintiff in the securities fraud class action is June 10, 2025. Contact Us To Participate or Learn More: If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to the pending class action lawsuit, please contact us: Frank R. Cruz The Law Offices of Frank R. Cruz, 2121 Avenue of the Stars, Suite 800, Century City, California 90067 Email us at: info@ Call us at: 310-914-5007 Visit our website at Follow us for updates on Twitter: If you inquire by email, please include your mailing address, telephone number, and number of shares purchased. To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Business Wire
28 minutes ago
- Business Wire
The Trade Desk to Launch Deal Desk – A Revolutionary Approach to Understanding and Managing Digital Advertising Deal Performance
VENTURA, Calif.--(BUSINESS WIRE)--Global advertising technology leader The Trade Desk (NASDAQ:TTD) today announced Deal Desk, a transformational new pillar of its Kokai platform that enables advertisers to manage their strategic one-to-one deals and upfront commitments with publishers. Deal Desk gives both advertisers and publishers unprecedented transparency and insight into the performance, quality, and pacing of their deals, and showcases premium internet alternatives when deals underperform. Digital advertising deals between advertisers and publishers, as well as inventory aggregators, command a large percentage of programmatic spend, but today many deals underperform thanks to lack of visibility into impression quality and pacing. In an industry first, Deal Desk leverages advanced AI to help advertisers and publishers understand deal performance, so they can address campaign optimization. Deal Desk also helps advertisers consider premium internet alternatives in the open market or in premium marketplaces such as the Sellers and Publishers 500 Plus*. "The Trade Desk is committed to improving the supply chain for digital advertising on the open internet, and improving deal performance is a vital element of this work,' said Will Doherty, SVP, Inventory Development, The Trade Desk. 'Deals have not kept pace with advances in AI and transparency that savvy media buyers and sellers have come to expect. Deal Desk represents a long overdue innovation for our industry and will help advance the strategic relationships between advertisers and their premium publisher partners.' Deal Desk incorporates a range of powerful new features and innovations, including: Advertisers can inspect the health and value of their deals, using Deal Quality Scores to understand when a deal offers unique value for their campaigns and when they can find better value in the open marketplace. Publishers can use new APIs or a UI to propose deals that fully describe their inventory with rich metadata and clearly defined terms. They can use the same Deal Quality Scores their buyers see to gain insight into the market for their inventory and discover actionable recommendations to help improve the value of their deals. Deal Desk will help automate deal activation and prioritization so that both advertisers and publishers can spend less time troubleshooting pacing and more time on strategic analysis and optimizations. New built-in expansion and cancelation features create mutual accountability and help advertisers easily include more relevant inventory when a deal is unable to deliver within the original terms. Initial publishers who have adopted Deal Desk for their private marketplace deals include industry leaders such as Disney. 'As more buyers shift toward biddable activation, we're focused on ensuring they have the tools, access, and flexibility they need to drive results,' said Jamie Power, SVP of Addressable Sales, Disney. 'We continue to put our advertisers first, and our relationship with The Trade Desk reflects our commitment to meeting advertisers where they are and evolving how we transact to deliver greater efficiency and performance.' Deal Desk will be available for beta testing in Q3 2025. *For more information on the Sellers and Publishers 500 Plus, please visit here.
